S-444,823 Explained

S-444,823 is a drug developed by Shionogi which is a cannabinoid agonist.^[1] It was developed as an antipruritic, and has moderate selectivity for the CB₂ subtype, having a CB₂ affinity of 18nM, and 32x selectivity over the CB₁ receptor. In animal studies it showed analgesic effects and strongly reduced itching responses, but without producing side effects such as sedation and catalepsy that are seen with centrally acting CB₁ agonists.^[2]

See also

• JTE 7-31
• RQ-00202730
• S-777,469

Notes and References

1. http://patentscope.wipo.int/search/en/detail.jsf?docId=WO2005016351 Arimura A. Novel Use of Cannabinoid Receptor Agonist. Patent WO 2005/016351
2. Odan M, Ishizuka N, Hiramatsu Y, Inagaki M, Hashizume H, Fujii Y, Mitsumori S, Morioka Y, Soga M, Deguchi M, Yasui K, Arimura A . 6 . Discovery of S-444823, a potent CB1/CB2 dual agonist as an antipruritic agent . Bioorganic & Medicinal Chemistry Letters . 22 . 8 . 2898–901 . April 2012 . 22421019 . 10.1016/j.bmcl.2012.02.050 .